Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib with GEMOX in Resectable Gallbladder Carcinoma
NCT04183712Phase 2Recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Jun 2020
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of afatinib in gallbladder carcinoma (2 arms), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Disease-Free Survival at 3 years. Started Jun 2020; status: recruiting.
02
Drugs
afatinib
03
Conditions
gallbladder carcinoma
Beyond the preview
Go deeper on NCT04183712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04183712.